Consistently, co-treatment with TAK1 inhibitor, 5Z-O, in AMPK-knockdown ovarian cancer cells resulted in suppression of cell proliferation, which was similar to the effect of AMPK activator PF-06409577 (Fig. 6c). Here, MAP3K7 is linked to ovarian carcinoma.